The role of fibrinolysis in the era of primary percutaneous coronary intervention

Thrombosis and Haemostasis

Volumn 105, Issue 3, 2011, Pages 390-395

  Halvorsen, Sigrun ^a   Huber, Kurt ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b WILHELMINEN HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALTEPLASE; CLOPIDOGREL; ENOXAPARIN; FIBRINOLYTIC AGENT; FONDAPARINUX; HEPARIN; PLACEBO; RETEPLASE; STREPTOKINASE; TENECTEPLASE;

ACUTE HEART INFARCTION; ADJUVANT THERAPY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; CORONARY REPERFUSION; DRUG EFFICACY; EMERGENCY CARE; FIBRINOLYSIS; HEART MUSCLE ISCHEMIA; HEART REINFARCTION; HUMAN; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THERAPY DELAY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; CARDIOLOGY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HEART CATHETERIZATION; HUMANS; MALE; MODELS, BIOLOGICAL; MYOCARDIAL INFARCTION; RISK; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 79952512990     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH10-08-0513     Document Type: Review

References (55)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
2. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
3. Widimsky P, Wijns W, Fajadet J, et al. Reperfusion therapy for ST elevation acute myocardial infarction in Europe: description of the current situation in 30 countries. Eur Heart J 2010; 31: 943-957.
4. Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Effectiveness of intravenous fibrinolytic treatment in acute myocardial infarction. Lancet 1986; 1: 397-402.
5. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17 187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
6. The GUSTO Investigators. An international randomized trial comparing four fibrinolytic strategies for acute myocardial infarction. N Engl J Med 1993; 329: 673-682.
7. GUSTO III investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med 1997; 337: 1118-1123.
8. ASSENT-2 Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354: 716-722.
9. Szemraj J, Stankiewicz A, Rozmyslowicz-Szerminska W, et al. A new recombinant fibrinolytic and antithrombotic agent with higher fibrin affinity - a staphylokinase variant. An in-vivo study. Thromb Haemost 2007; 97: 1037-1045. (Pubitemid 46939219)
10. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.Indications for fibrinolytic therapy in suspected acute myocardialinfarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994; 343: 311-322.
11. Sinnaeve P, Van de Werf F. Enoxaparin and fibrinolysis: ExTRACTing prognosis from bleeding complications. Eur Heart J 2010; 31: 2077-2079.
12. Van de Werf F, Barron HV, Armstrong PW, et al.; ASSENT-2 Investigators. Assessment of the Safety and Efficacy of a New Thrombolytic. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA. Eur Heart J 2001; 22: 2253-2261.
13. Boersma E, Maas ACP, Deckers JW, et al. Early fibrinolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996; 348: 771-775. (Pubitemid 26308479)
14. De Luca G, Marino P. Advances in antithrombotic therapy as adjunct to reperfusion therapies for ST-segment elevation myocardial infarction. Thromb Haemost 2008; 100: 184-195.
15. Huisse M-G, Ajzenberg N, Feldman L et al. Microparticle-linked tissue factor activity and increased thrombin activity play a potential role in fibrinolysis failure in ST-segment elevation myocardial infarction. Thromb Haemost 2009; 101: 734-740.
16. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179-1189. (Pubitemid 40397259)
17. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366: 1607-1621.
18. ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358: 605-613.
19. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354: 1477-1488.
20. Sabatine MS, Morrow DA, Dalby A, et al. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J Am Coll Cardiol 2007; 49: 2256-2263. (Pubitemid 46863476)
21. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. J Am Med Assoc 2006; 295: 1519-1530.
22. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous fibrinolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003; 361: 13-20. (Pubitemid 36050955)
23. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate fibrinolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003; 24: 94-104.
24. Andersen HR, Nielsen TT, Rasmussen K, et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003; 349: 733-742. (Pubitemid 37010777)
25. Mehta RH, Bufalino VJ, Pan W, et al. Achieving rapid reperfusion with primary percutaneous coronary intervention remains a challenge: insights from American Heart Association's Get With the Guidelines program. Am Heart J 2008; 155: 1059-1067.
26. Nallamothu BK, Bates ER, Herrin J, et al. Times to treatment in transfer patients undergoing primary percutaneous coronary intervention in the United States: National Registry of Myocardial Infarction (NRMI)-3/4 analysis. Circulation 2005; 111: 761-767. (Pubitemid 40250637)
27. Kalla K, Christ G, Karnik R, et al; Vienna STEMI Registry Group. Implementation of guidelines improves the standard of care: the Viennese registry on reperfusion strategies in ST-elevation myocardial infarction. Circulation 2006; 113: 2398-2405.
28. Boersma E; Primary Coronary Angioplasty vs. Thrombolysis Group. Does time matter? A pooled analysis of randomized clinical trials comparing primary percutaneous coronary intervention and in-hospital fibrinolysis in acute myocardial infarction patients. Eur Heart J 2006; 27: 779-788.
29. Morrison LJ, Verbeek PR, McDonald AC, et al. Mortality and prehospital fibrinolysis for acute myocardial infarction: A meta-analysis. J Am Med Assoc 2000; 283: 2686-2692. (Pubitemid 30337331)
30. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. on behalf of the CAPTIM study group. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study. Lancet 2002; 360: 825-829.
31. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856. (Pubitemid 37517811)
32. Danchin N, Blanchard D, Steg PG, et al. for the USIC 2000 investigators. Impact of prehospital fibrinolysis for acute myocardial infarction on 1-year outcome. Results from the French nationwide USIC 2000 registry. Circulation 2004; 110: 1909-1915.
33. Bonnefoy E, Steg PG, Boutitie F, et al. Comparison of primary angioplasty and pre-hospital fibrinolysis in acute myocardial infarction (CAPTIM) trial: a 5-year follow-up. Eur Heart J 2009; 30: 1598-1606.
34. De Luca G, Suryapranata H, Zijlstra F, et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol 2003; 42: 991-997. (Pubitemid 37108581)
35. De Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: Every minute of delay counts. Circulation 2004; 109: 1223-1225. (Pubitemid 38372780)
36. Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction is timing (almost) everything? Am J Cardiol 2003; 92: 824-826. (Pubitemid 37163578)
37. Betriu A, Masotti M. Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis. Am J Cardiol 2005; 95: 100-101. (Pubitemid 40051119)
38. Terkelsen CJ, Lassen JF. Treatment delays in ST elevation myocardial infarction. Br Med J 2008; 336: 401-402. (Pubitemid 351310869)
39. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006; 114: 2019-2025. (Pubitemid 44706877)
40. Wijns W, Kolh P, Danchin N, et al. Guidelines on myocardial revascularization. Eur Heart J 2010; 31: 2501-2555.
41. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 2006; 367: 569-578.
42. Ellis SG, Tendera M, de Belder MA, et al; FINESSE Investigators. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008; 358: 2205-2217. (Pubitemid 351724450)
43. Gershlick AH, Stephens-Lloyd A, Hughes S, et al; REACT Trial Investigators. Rescue angioplasty after failed fibrinolytic therapy for acute myocardial infarction. N Engl J Med 2005; 353: 2758-2768. (Pubitemid 43016815)
44. Danchin N, Coste P, Ferrières J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction: data from the french registry on acute ST-elevation myocardial infarction (FAST-MI). Circulation 2008; 118: 268-276.
45. Scheller B, Hennen B, Hammer B et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003; 42: 634-641. (Pubitemid 37000177)
46. Fernandez-Avilés F, Alonso JJ, Castro-Beiras A et al. Routine invasive strategy within 24 hours of thrombolysis versus ischemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004; 364: 1045-1053..
47. Le May MR, Wells GA, Labinaz M et al. Combined angioplasty and pharmalogical intervention versus thrombolysis alone in acute myocardial infarction. J Am Coll Cardiol 2005; 46: 417-424. (Pubitemid 41040280)
48. Di Mario C, Dudek D, Piscione F, et al. Immediate angioplasty versus standard therapy with rescue angioplasty after fibrinolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008; 371: 559-568. (Pubitemid 351232030)
49. Cantor WJ, Fitchett D, Borgundvaag B, et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009; 360: 2705-2718.
50. Bohmer E, Hoffmann P, Abdelnoor M, et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after fibrinolysis in acute myocardial infarction in areas with very long transfer distances. Results of the NORDISTEMI (NORwegian study on DIstrict treatment of STelevation myocardial infarction). J Am Coll Cardiol 2010; 55: 102-110.
51. Huber K, Goldstein P, Danchin N, et al. Network models for large cities: the European experience. Heart 2010; 96: 164-169.
52. Borgia F, Goodman SG, Halvorsen S, et al. Early routine percutaneous coronary intervention after fibrinolysis vs. standard therapy in ST-segment elevation myocardial infarction: a meta-analysis. Eur Heart J 2010; 31: 2156-2169.
53. Armstrong PW, Gershlick A, Goldstein P, et al. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J 2010; 160: 30-35.e1.
54. Ting HH, Rihal CS, Gersh BJ, et al. Regional systems of care to optimize timeliness of reperfusion therapy for ST-elevation myocardial infarction: the Mayo Clinic STEMI Protocol. Circulation 2007; 116: 729-736. (Pubitemid 47255990)
55. Lambert L, Brown K, Segal E, et al. Association between timeliness of reperfusion therapy and clinical outcomes in ST-elevation myocardial infarction. J Am Med Assoc 2010; 303 : 2148-2155.